Johnson and Johnson
The top 5 pharma M&A deals of 2020
Nothing should stand in the way of coronavirus vaccine access, says J&J
Johnson & Johnson: Partnering to eliminate disease
Zytiga generics looming as US court nixes J&J patent
J&J builds case for HIV vaccine ahead of pivotal trial readout
J&J tops the pharma market cap charts – but for how long?
J&J seals $2.1bn deal on sale of major diabetes devices firm
Johnson & Johnson (J&J) has announced that Fortive Corp has made an offer of about $2.7 billion in cash for its Advanced Sterilisation Products (ASP) business.
J&J offered $2.7 billion for sterilisation business by Fortive